Navigation Links
Halo Pharmaceutical Welcomes Al Rosenston as its Vice President, Business Development
Date:1/26/2009

WHIPPANY, N.J., Jan. 26 /PRNewswire/ -- Adding to its strong executive team, Halo Pharmaceutical today announced the addition of Allen M. Rosenston, a thirty-five year pharmaceutical industry veteran, as Halo's new Vice President of Business Development. Al comes to Halo from a long and distinguished career at Abbott Laboratories where he held diverse roles in operations, business development, and related business functions. "The addition of Al to the Halo business development team is a significant achievement. Al has deep experience within the pharmaceutical industry. He developed Abbott's domestic Contract Pharmaceutical Manufacturing Business Unit and, at the time of his retirement, he was responsible for the global finished goods contract manufacturing business," according to Mohd Asif, Halo's Chief Financial Officer.

Al comes to Halo shortly after Halo's acquisition of its Whippany, NJ facility, a facility which has been producing various dosage forms for 35 years. "I am thrilled to be part of the Halo Pharmaceutical team, and to build on the legacy of this outstanding facility and group of talented people with an average seniority of over 20 years. Based on my discussions with the new Halo team, this is a unique opportunity to create a world-class pharmaceutical services company right in the heart of New Jersey. Maintaining focus on quality, service, and compliance, along with the flexible manufacturing capabilities of the Whippany facility, will create a high-level of interest with prospective customers. I anticipate us to be highly competitive when overall service value is assessed."

Halo capabilities include an impressive array of formulation services, operations for the aseptic filling of topical ointments, solid dosage forms (tablets and capsules), liquids, suppositories, associated packaging (tablet, powder, liquids and HUD) and ample laboratory space for formulation development, pre-clinical and clinical supplies and support of commercial operations. An additional asset is the site's capability to manufacture controlled substances (C2-C5) and an API manufacturing unit with an outstanding track-record of meeting DEA requirements.

Al joined Halo on January 5, 2009, and can be reached at arosenston@halopharma.com or at 973-428-4087.

About Halo Pharmaceutical

Halo Pharmaceutical, headquartered in Whippany, NJ, is a full-service, specialty pharmaceutical company, offering state-of-the-art contract manufacturing, early stage formulation development and laboratory services to the pharmaceutical and related industries. Halo is currently a supplier of choice to a number of large and medium size brand pharmaceutical companies for important lifecycle products. Contract manufacturing capabilities include the ability to conduct aseptic filling, granulation, blending, tableting, coating, packaging, and related warehousing operations. Halo Pharmaceutical is a privately-held company.


'/>"/>
SOURCE Halo Pharmaceutical
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. KV Pharmaceutical Suspends Product Manufacturing, Shipping
2. KV Pharmaceuticals Launch of Gestiva(TM) Delayed
3. Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
4. Caraco Pharmaceutical Laboratories, Ltd. to Announce Third Quarter of Fiscal Year 2009 Results on January 29, 2009
5. University Medical Pharmaceuticals Appoints Tom Roche as Senior Vice President, Global Sales and Marketing
6. Amylin Pharmaceuticals to Webcast Year-End Results
7. Renhuang Pharmaceuticals, Inc. Engages New Independent Auditor
8. Abbott Opens New Pharmaceutical Research Laboratory in Singapore
9. Law Firm Freedland Russo Spearheads Record-Setting Whistleblower Case Against Pharmaceutical Giant Eli Lilly -- Firm Expands Offices to Include L.A. Entertainment Branch
10. NUCRYST Pharmaceuticals appoints a new director
11. Peptimmune Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... team BioCellection won the $30,000 Perlman Grand Prize of the 2016 Wharton Business ... Award, the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... Canadian Celiac Association (CCA), is pleased to announce the launch of the ... nutritional articles, recipes, and more. The purpose of the GFCP Scoop ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... ... 2016 , ... CURE Media Group , the nation’s ... today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci Cancer Center in ... Oncology Nursing , which honors nurses who have dedicated their careers to helping ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... 27, 2016   ... in Recurring Consumable Sales  Clinical sales grow ... Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the ... for the first quarter ended March 31, 2016 and ... of its commercial strategy. First Quarter 2016 ...
Breaking Medicine Technology: